Evidence map›Paper›PMID 41614616›Full record

ArticleThe Journal of antimicrobial chemotherapy2026

Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa.

Yoshinori Yamano, Miki Takemura, Christopher Longshaw, Boudewijn L M DeJonge, Naoki Ishibashi, Ryuta Ishii, Dai Miyagawa, Rio Nakamura, Miho Kuroiwa, Yoshino Ishioka and 4 more

Abstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Broadly Defined Antibiotic Adjuvants forThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yoshinori YamanoDrug Discovery Research Division, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.ORCID 0000-0002-7860-8863
Miki TakemuraDrug Discovery Research Division, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.
Christopher LongshawScientific Affairs, Shionogi B.V., London, UK.
Boudewijn L M DeJongeUS Medical Affairs, Shionogi Inc., Florham Park, NJ, USA.
Naoki IshibashiDrug Discovery Research Division, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.
Ryuta IshiiDrug Discovery Research Division, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.
Dai MiyagawaDrug Discovery Research Division, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.
Rio NakamuraDrug Discovery Research Division, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.
Miho KuroiwaDrug Discovery Research Division, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.
Yoshino IshiokaDrug Discovery Research Division, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.
Takumi AdachiDrug Discovery Research Division, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.
Masatomo RokushimaDrug Discovery Research Division, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.
Hideki MakiDrug Discovery Research Division, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.
Takafumi SatoDrug Discovery Research Division, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.

Funding

Shionogi & Co. Ltd.
6 · The paper itself

Abstract

objectivesUnderstand how mutations upstream of pvdS and fecI in Pseudomonas aeruginosa PAO1 lead to reduced susceptibility to cefiderocol, a siderophore cephalosporin. MATERIALS AND

methodsWhole-genome sequencing, gene complementation and inactivation, mRNA expression, siderophore quantification and supplementation were carried out with mutants that showed reduced susceptibility to cefiderocol.

resultsWhole-genome sequencing, combined with gene complementation studies, with isolated mutants that showed 4-fold reduced susceptibility to cefiderocol identified mutations within the Fur-box of promoter regions upstream of pvdS and fecI. The pvdS promoter mutation led to increased pvdS transcription, resulting in increased pyoverdine production, as well as reduced transcription of other iron transport-related genes, including piuA an iron transporter responsible for cefiderocol uptake. The down-regulation of piuA, rather than competition for iron between pyoverdine and cefiderocol, was responsible for the decreased cefiderocol susceptibility. The fecI mutant demonstrated increased transcription of fecI and fecA, and the expression level of piuA in the fecI mutant was not related to reduced cefiderocol susceptibility, indicating a different mechanism for the reduced cefiderocol susceptibility in this mutant. Sequence analyses of over 35 000 clinical P. aeruginosa isolates did not identify isolates with the pvdS mutation, and only one isolate with the fecI mutation.

conclusionsThese data highlight different mechanisms by which P. aeruginosa attempts to evade the action of cefiderocol by exploiting the complexities of iron haemostasis in bacteria. The absence of such mutants in the clinic suggests that such mutations may be detrimental for P. aeruginosa to survive in the clinical environment.

Indexed as

Anti-Bacterial AgentsBacterial Outer Membrane ProteinsBacterial ProteinsCephalosporinsDrug Resistance, BacterialPseudomonas aeruginosaCefiderocolGene Expression Regulation, BacterialGenetic Complementation TestIronMicrobial Sensitivity TestsMutationOligopeptidesPromoter Regions, GeneticRepressor ProteinsSiderophoresAnti-Bacterial AgentsBacterial Outer Membrane ProteinsBacterial ProteinsCefiderocolCephalosporinsIronOligopeptidesPvdS protein, Pseudomonas aeruginosapyoverdinRepressor ProteinsSiderophoresSigma Factor

Identifiers

PMID41614616
PMCPMC12856659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.